INTRODUCTION
Just as the worldwide HIV pandemic disproportionately affects populations in low-income and middleincome countries (LMIC), especially sub-Saharan Africa (SSA), so too does the parallel epidemic of HIV-associated malignancies (HIVAM) that are often the most common cancers overall in highly HIV-endemic countries. For HIV itself, the last 2 decades have witnessed a remarkable global effort for prevention, treatment, and research, resulting from worldwide advocacy and multilateral investment, with a reach that now extends to some of the remotest villages in some of the world's poorest countries. A comparable effort for HIVAM is taking shape. In this review, we summarize recent developments for HIVAM in LMIC, highlighting progress, challenges, and opportunities in this emerging field.
EPIDEMIOLOGY
The global HIV epidemic is concentrated in LMIC, and SSA specifically, with 69% of the worldwide HIV-infected population living in this region in 2015 [1] . In SSA, public-sector antiretroviral therapy (ART) provision in most countries began in the mid-2000s, with 11.8 million individuals now receiving ART or 46% or those living with HIV. Importantly, with accumulating evidence demonstrating individual-level and populationlevel benefits of earlier ART, WHO guidelines for ART eligibility in LMIC have become progressively more inclusive. All HIV-infected individuals are now recommended to receive ART irrespective of CD4 þ cell counts [2] , although many countries have yet to a UNC Project-Malawi, Lilongwe, Malawi, b implement treating all HIV-positive people due to resource limitations and logistical issues. As a result, despite dramatic increases in ART availability worldwide, the coverage gap in most LMIC remains considerable. Moreover, achievements in ART scale-up are fragile and conditional on ongoing commitments by governments and external donors, with potential for gains to be reversed if commitments are not firm. Finally, despite ambitious targets and incremental progress to provide earlier ART, HIV-infected individuals in LMIC still typically initiate ART with advanced immunosuppression [3] , accruing significant risk of morbidity compared with asymptomatic patients treated before CD4 þ cell counts depletion or HIV-related complications. LMIC therefore have substantial HIV-infected populations who still cannot access timely HIV diagnosis and treatment, similar to early years before publicsector ART availability, along with large numbers of patients having well controlled HIV on long-term ART, for whom epidemiologic transitions toward chronic noncommunicable disease complications of HIV are occurring as in resource-rich settings.
With respect to HIVAM epidemiology, data from high-income countries demonstrate that the proportion of HIV-related deaths due to cancer is increasing [4] , HIVAM are transitioning from AIDSdefining cancers (ADC) to non-AIDS defining cancers (NADC) [5] , and CD4 þ cell counts and HIV control at cancer diagnosis are improving even for patients with ADC [6] . However, several factors make it difficult to fully assess the degree to which trends in resourcerich settings are replicated in LMIC, even aside from less mature ART coverage. There are severe deficits in cancer registration in LMIC, particularly SSA and even for registries contributing to WHO global cancer estimates, including low-population coverage, significant urban bias, and low data quality [7 && ]. Even in well enumerated HIV cohorts retained in care on chronic ART, ascertainment of cancer diagnoses is poor [8 & ]. Diagnostic pathology in SSA is also limited, and often under-utilized when it exists [9] . Even for superficial tumors that can be visualized and often are diagnosed clinically in SSA, like Kaposi sarcoma and ocular surface squamous neoplasia, clinical diagnosis performs poorly compared with pathology with positive predictive value less than 80% [10
For more visceral tumors, not only pathology limitations but inadequate surgical or interventional capabilities to obtain diagnostic tissue results in these tumors also being underrepresented. In Malawi, investments to build and improve pathology infrastructure led to the 'discovery' of HIV-associated multicentric Castleman disease (MCD), which is scarcely reported from SSA and in Malawi was often misdiagnosed as lymphadenitis due to tuberculosis or HIV [12,13 & ]. Finally, because cancer diagnosis and care are highly centralized in LMIC, there is a significant referral bias affecting all cancer burden descriptions, such that tumors at the most indolent and fulminant ends of the clinical spectrum may be underrepresented, as patients may die before presenting to tertiary centers when severely ill or forego spending time and money to seek care for mild symptoms. Even in Botswana, a country with a relatively small population and high per capita resource level relative to many of its neighbors, as well as one of the region's most successful national ART programs, a median 13-month delay has been documented from symptom onset to receipt of subspecialty oncology care across diverse cancer patients [14 && ]. Despite these caveats, data are emerging that ART availability in LMIC may be producing trends which at least partly resemble resource-rich settings. Perhaps not surprisingly, similar trends to high-income countries are most evident thus far in middle-income countries, where ART coverage and cancer diagnostic infrastructure are better than low-income countries. For instance, in Botswana, ART expansion has resulted in significant decreases in age-specific cancer risk for HIV-infected individ- 
KAPOSI SARCOMA
As noted above, Kaposi sarcoma is the most frequent cancer in many SSA countries. Patients with HIV-associated Kaposi sarcoma in SSA have higher mortality, higher risk of immune reconstitution inflammatory syndrome (IRIS), and more frequently detectable Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood than cohorts in resource-rich settings [25] . For Kaposi sarcoma, the KART study conducted in Durban remains the only clinical trial completed in SSA in the ART era and demonstrated better tumor response but similar overall survival at 1 year for HIV-infected patients with primarily advanced Kaposi sarcoma treated with ART and chemotherapy (ABV; doxorubicin, bleomycin, and vincristine) compared with ART alone [26] . Two ongoing multinational studies co-sponsored by the AIDS Clinical Trials Group and AIDS Malignancy Consortium are evaluating treatment strategies for limited and advanced Kaposi sarcoma, respectively [27, 28] . The limited Kaposi sarcoma trial is comparing ART alone with ART and oral etoposide, and the advanced Kaposi sarcoma trial is comparing ART for all patients with oral etoposide, intravenous paclitaxel, or intravenous bleomycin and vincristine. Final results from both studies will inform regional practice. Apart from clinical trials at urban SSA referral centers, we have demonstrated in Malawi that ART with chemotherapy (paclitaxel or bleomycin/vincristine) can produce excellent outcomes even in extremely remote areas, when implemented using standardized algorithms with appropriate levels of support for nurses and clinical officers [29 && ]. In this cohort, anemia and low BMI were significantly associated with worse survival.
Associations between anemia and poor outcomes are interesting given the Malawi experience with MCD, which has been observed almost exclusively among HIV-infected individuals with excellent long-term HIV control on ART often without evident Kaposi sarcoma [12, 13 & ]. Patients with MCD have had severe illness including profound anemia with markedly elevated plasma KSHV levels, and have typically responded to chemotherapy but relapsed shortly after chemotherapy was discontinued with subsequently poor outcomes in the absence of rituximab availability. The association between anemia and worse survival for HIV-associated Kaposi sarcoma raises questions as to whether concurrent MCD, KSHV-associated inflammatory cytokine syndrome, or a virologic, inflammatory, and/or immunologic milieu at least partially resembling these disorders, may occur in some Kaposi sarcoma patients in SSA and contribute to worse outcomes. Work in Uganda has suggested that immune activation via induction of indoleamine dioxygenase may be associated with reduced Even with widespread availability of HPV vaccination, effects on HPV-associated cancer incidence will not be immediate. Moreover, the quadrivalent vaccine that has been most widely adopted is less immunogenic in HIV-infected women with severe immunosuppression [39] , and vaccination has yet to be applied in most LMIC to atrisk populations other than school-age girls, including boys. The quadrivalent vaccine also provides limited protection against oncogenic HPV subtypes other than 16 and 18, with non16/18 subtypes being responsible for approximately 20% of cervical cancer globally [40] , although the proportion of cases attributable to 16/18 versus non16/18 HPV subtypes does not appear to differ in SSA by HIV status [41 && ]. Vaccine scale-up must be accompanied by screening scale-up, for which high-level evidence exists that this can be implemented on a large scale using visual inspection with acetic acid (VIA) or HPV testing, with consequent mortality reductions related to cervical cancer [42, 43] . Substantial progress in scaling up VIA has been made in many LMIC countries, for example Zambia, where a large national screening program has found an extremely high burden of high-grade dysplasia and cancer especially among women with HIV [44 && ,45 && ]. Other methods to optimize screening are under evaluation, including evaluations of HPV testing specifically among HIV-positive women and use of self-collected specimens [46, 47] . As these efforts move forward, best practices for cervical cancer screening in LMIC will become better defined to achieve more immediate declines in disease-specific incidence and mortality, whereas longer term effects of population-level HPV immunization are awaited.
Despite vaccination and screening, cervical cancer cases continue to occur, and treatment in SSA is made difficult by scarce or absent radiotherapy in many countries [48] , as is typically required for women with stage IB2 or greater tumors who cannot be treated with surgical resection alone. Overall, cervical cancer treatment studies have been few, but the AIDS Malignancy Consortium has recently completed a study evaluating the feasibility of cisplatin-based chemoradiation specifically among HIV-infected women with locally advanced cervical cancer in Zimbabwe [49] .
NON-HODGKIN LYMPHOMA
Although less frequent than Kaposi sarcoma or cervical cancer, non-Hodgkin lymphoma (NHL) is most commonly treated with curative intent in LMIC among HIVAM, building on experience in resource-rich settings showing that HIV-positive NHL patients can be treated with similar intensity and achieve similar outcomes to those without HIV in the ART era. Despite availability in LMIC of generic chemotherapy drugs that remain key components of NHL treatment even in high-income countries, stock outs are common, supportive care is limited including often absent hematopoietic growth factors, infusional, and higher intensity regimens are often impractical, infectious complications during chemotherapy and anti-infective prophylaxis strategies are poorly defined, and newer noncytotoxic agents including rituximab are often not available. In Malawi, HIV-infected patients with aggressive NHL present with advanced bulky disease and poor performance status, although interestingly with less tumor bulk and shorter symptom durations than HIV-negative patients, perhaps reflecting primary care and referral networks established for HIV which are absent for HIV-uninfected populations [50 & ]. With appropriate monitoring and dose adjustment, even unselected HIV-infected patients can be treated with standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), with comparable treatment intensity with HIV-negative patients, reasonably good outcomes, and deaths primarily related to relapsed/ refractory NHL, although treatment-related mortality is also considerable. Outcomes are principally determined by NHL disease characteristics (international prognostic index score) rather than HIV status, and neutropenia is by far the most frequent toxicity among HIV-positive patients who might be easily addressed with greater availability of hematopoietic growth factors. On the basis of our experience and other similar reports from SSA [51-53], continued efforts to diagnose patients earlier, treat them with standardized protocols, improve supportive care, and incorporate newer noncytotoxic therapies can likely increase cure rates substantially even for HIV-infected patients in highly resource-limited settings [54] . Strategies testing lower intensity, oral, metronomic approaches are also under evaluation with some promising early experience [55, 56] .
OTHER CANCERS
Many other HIVAM occur with appreciable frequency in LMIC, and many groups are developing research programs specifically focused on these. For instance, for conjunctival squamous cell carcinoma, efforts to screen HIV-infected patients in Kenya using toluidine blue staining have been described [57 & ], as well as suggestions that resection followed by brachytherapy may be well tolerated and associated with low recurrence rates in South Africa [58 & ]. However, given the relatively immature nature of the field overall, there are not major recent studies for other HIVAM in LMIC that would clearly merit inclusion in this review, although it is hoped that more data related to these tumors will soon be forthcoming.
CONCLUSION
The field of HIVAM in LMIC is in its infancy. Building on remarkable progress for HIV, there are encouraging initial efforts to define unique pathogenesis and best approaches to treatment and prevention for HIVAM in LMIC in which burden is greatest. Continued investments for HIVAM in LMIC can also likely catalyze a broader cancer care and research agenda, with substantial benefits to HIV-positive and HIV-negative cancer patients worldwide.
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